Product logins

Find logins to all Clarivate products below.


Alison Isherwood

Director, Epidemiology & Real-World Evidence

Dr. Alison Isherwood is a Director in Clarivate’s Commercial Strategy Consulting Epidemiology & Real-World Evidence team.

Alison has over 16 years of consultancy experience in healthcare and life sciences consultancy, specializing in epidemiological and RWE-based insights and solutions. Her role is to use secondary data and US and European real-world data (RWD) to provide strategic epidemiological insights for business stakeholders in commercial and HEOR roles.

Alison held the roles of Research Scientist at Evidera designing and executing RWE-based outcomes research studies. Prior to this, she the Director of Epidemiology for DRG’s Syndicated Epidemiology team where she gained considerable experience in patient population sizing with incidence and prevalence risk-based forecast modelling across a portfolio of 200 diseases in over 40 countries.

She holds a Doctoral degree from the University of Reading (UK), and an MSc in Epidemiology, an MRes in Life Sciences and a BSc in Medical Microbiology all from the University of Edinburgh.


arrow_forward
Get in touch with Alison

Latest news

News October 7, 2025
Winbond Selects IPfolio from Clarivate

Global Electronics Manufacturer to Modernize IP Management and Drive Digital Transformation London, U.K. October 7, 2025. Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced that…

News October 6, 2025
Clarivate to Report Third Quarter 2025 Results on October 29, 2025

London, U.K., October 6, 2025 – (PR Newswire) – Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today it will report its financial results for the third…

News October 1, 2025
Clarivate delivers new AI-powered solutions within Innography for competitive benchmarking and standard-essential patent analysis

AI Classifier delivers patent classification with up to 97% first-pass accuracy for portfolio benchmarking, while SEP Analyzer enhances reporting with clear, intuitive visualizations London, U.K. October 1, 2025. Clarivate Plc…

Related resources

Managing uncertainty for medicine in Washington Managing uncertainty for medicine in Washington
Blog May 15, 2025
Managing uncertainty for medicine in Washington
Clinical research Early drug development research Market Access Pharma Portfolio strategy Research Research and development Research commercialization Research evaluation and management
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Blog April 2, 2025
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Market Access Pharma Portfolio strategy Regulatory Research commercialization
Five Medtech Trends to Watch in 2025 Five Medtech Trends to Watch in 2025
Blog February 11, 2025
Five Medtech Trends to Watch in 2025
Medical technology Medtech Medtech Resource Center
The trends to watch in 2025 The trends to watch in 2025
Blog January 8, 2025
The trends to watch in 2025